Deal-making news last week included Benitec Biopharma’s collaboration with Axovant Sciences on rare disease drug BB-301, which sent the Australian firm’s shares more than doubling. On the M&A front, BioCryst’s merger with Idera was resisted by shareholders. Company news included disappointment for Regulus Therapeutics when it paused clinical studies and slashed its work force. Also attracting attention was Pfizer’s announcement to defer planned drug price hikes and Pfizer’s decision to reorganize its business.
Not developing your gene therapy? Call Axovant
If you run a small-cap biotech company and have a gene therapy asset languishing in your patent portfolio then this could be your lucky day: Axovant is buying, commented EP Vantage, the editorial arm of the Evaluate group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze